How should recurrent shingles be managed in a 67-year-old male with Waldenström macroglobulinemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Recurrent Shingles in a 67-Year-Old Male with Waldenström Macroglobulinemia

This patient requires antiviral prophylaxis with valacyclovir or acyclovir due to the profound immunosuppression from Waldenström macroglobulinemia and its treatment, which places him at high risk for recurrent varicella-zoster virus (VZV) reactivation.

Immediate Antiviral Management

The recurrent shingles episodes indicate significant immunocompromise from the underlying lymphoproliferative disorder. While the provided guidelines focus on WM treatment rather than infection prophylaxis specifically, the immunosuppressive nature of WM and its therapies creates substantial VZV reactivation risk 1.

Key prophylactic approach:

  • Long-term suppressive antiviral therapy with valacyclovir 500 mg daily or acyclovir 400-800 mg twice daily
  • Continue prophylaxis throughout active WM treatment and for at least 6-12 months after completing immunosuppressive therapy
  • HSV and HZV prophylaxis is beneficial for patients requiring extensive WM treatment 1

Assessment of Underlying WM Disease Activity

The recurrent infections may signal:

Active disease requiring treatment - Evaluate for:

  • Hemoglobin <10 g/dL
  • Platelets <100 × 10⁹/L
  • Bulky adenopathy or organomegaly
  • Constitutional symptoms
  • IgM-related complications (hyperviscosity, neuropathy, cryoglobulinemia)

If symptomatic WM is present, treatment options based on disease severity 2:

For Modest Disease Burden:

  • Rituximab monotherapy (375 mg/m² weekly × 4 weeks) without maintenance 3
  • Avoid rituximab maintenance as it increases infection risk without proven benefit in WM 2

For Severe/Bulky Disease:

  • Bendamustine-rituximab (preferred first-line) 2
  • Dexamethasone-rituximab-cyclophosphamide (DRC) as alternative, particularly for non-bulky disease 3

Critical Infection Prevention Measures

Comprehensive prophylaxis strategy 1:

  • VZV prophylaxis: Valacyclovir or acyclovir (as above)
  • Pneumocystis jiroveci prophylaxis: Trimethoprim-sulfamethoxazole (highly recommended during active treatment)
  • Hepatitis B screening: Required before initiating therapy
  • Vaccinations: SARS-CoV-2 and seasonal influenza vaccines (though response may be blunted)

Common Pitfalls to Avoid

  1. Do not treat based on IgM levels alone - IgM elevation without symptoms is not an indication for therapy 1

  2. Avoid purine nucleoside analogues (fludarabine, cladribine) in this patient:

    • Associated with increased risk of transformation and myelodysplasia 3
    • Cause profound immunosuppression worsening infection risk
    • Damage stem cells if future transplant needed 4
  3. Watch for rituximab IgM flare - Can cause paradoxical IgM increase for up to 4 months, potentially triggering hyperviscosity 3. Consider plasmapheresis if symptomatic.

  4. Do not discontinue antiviral prophylaxis prematurely - Continue throughout immunosuppressive therapy and extended period after completion

Treatment Selection Algorithm

If WM is asymptomatic (preserved hemoglobin, no organomegaly, no constitutional symptoms):

  • Observe without WM-directed therapy 3
  • Initiate antiviral prophylaxis regardless
  • Monitor every 3-6 months

If WM requires treatment:

  • Start antiviral prophylaxis immediately
  • Add PCP prophylaxis
  • Choose WM therapy based on disease burden (bendamustine-rituximab for bulky disease, rituximab alone for modest disease)
  • Continue prophylaxis throughout treatment and 6-12 months post-therapy

The recurrent shingles itself is a marker of immunocompromise that warrants aggressive prophylactic measures, regardless of whether the underlying WM currently requires treatment. The goal is preventing further VZV reactivations while addressing any active lymphoproliferative disease contributing to immune dysfunction.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.